Pediatric Oncology

Top Story

FDA grants orphan drug designation to dactinomycin formulation for Ewing's sarcoma

July 30, 2015

The FDA granted orphan drug designation to a formulation of dactinomycin for the treatment of children with Ewing’s sarcoma, according to a press release from the drug’s manufacturer.

The drug product is a formulation of dactinomycin incorporated into a proprietary antinuclear antibody (ANA)-conjugated nanoemulsion (NanoSmart Pharmaceuticals). This is the second drug product that uses NanoSmart Pharmaceuticals’ proprietary drug delivery platform.

In the Journals

Combination of cladribine, cytarabine improves survival for children with LCH

July 28, 2015
The combination of cladribine and cytarabine conferred high survival rates among children with high-risk, risk organ-positive Langerhans cell histiocytosis, according to…
In the Journals

Ethanol locks reduce central venous catheter-associated bloodstream infections in children with cancer

July 27, 2015
Ethanol locks prevented central venous catheter-associated bloodstream infections in pediatric patients with cancer, according to the results of a randomized…
SupplementPublication Exclusive

Perspectives from ASCO 2015: A HemOnc Today Special Report

HemOnc Today, July 25, 2015
This year’s ASCO Annual Meeting featured the theme “Illumination and Innovation: Transforming Data into Learning.”As such, meeting organizers selected…
CME
Hematology Oncology Case Consults

The Patient with Multiple Myeloma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with multiple myeloma.
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
FDA News

FDA grants orphan drug designation to dactinomycin formulation for Ewing's sarcoma

July 30, 2015
The FDA granted orphan drug designation to a formulation of dactinomycin for the treatment of children with Ewing’s sarcoma, according to a…
In the Journals

Combination of cladribine, cytarabine improves survival for children with LCH

July 28, 2015
The combination of cladribine and cytarabine conferred high survival rates among children with high-risk, risk organ-positive Langerhans cell…
In the Journals

Ethanol locks reduce central venous catheter-associated bloodstream infections in children with cancer

July 27, 2015
Ethanol locks prevented central venous catheter-associated bloodstream infections in pediatric patients with cancer, according to the results of a…
SupplementPublication Exclusive

Perspectives from ASCO 2015: A HemOnc Today Special Report

HemOnc Today, July 25, 2015
This year’s ASCO Annual Meeting featured the theme “Illumination and Innovation: Transforming Data into Learning.”As such, meeting…

What are symptoms of cancer in children?

July 17, 2015
Cancer is a difficult disease to detect in children, as symptoms may be minimal or even nonexistent.Cancer is the second leading cause of death among…
FDA News

FDA grants orphan drug designation to Anisina for neuroblastoma

July 16, 2015
The FDA granted orphan drug designation to the chemotherapy drug Anisina for the treatment of pediatric patients with neuroblastoma, according to a…
Thomas J. Smith, MD In the Journals

ASCO updates guidelines on hematopoietic colony-stimulating factors

July 14, 2015
ASCO has updated its clinical practice guidelines regarding the use of hematopoietic colony-stimulating factors to lower the risk for febrile…
In the Journals

Neoadjuvant chemotherapy demonstrates favorable outcomes in pediatric germ cell tumors

July 14, 2015
Children with newly diagnosed nongerminomatous germ cell tumors who received neoadjuvant chemotherapy with or without second-look surgery achieved…
Daniel M. Green In the Journals

Doxorubicin can be omitted from postoperative Wilms’ tumor treatment

July 13, 2015
The exclusion of doxorubicin from standard postoperative treatment did not worsen EFS in children with stage II to III intermediate-risk Wilms’…
Industry News

Nurse researcher named journal editor

July 5, 2015
Kristin Stegenga, PhD, RN, CPON, has been named editor of Journal of Pediatric Oncology Nursing.The journal, an official publication of the…
More Headlines »
morganatic-roan morganatic-roan